 |
 Video: What is a Stock Split?
|
|
|
| Reneo Pharmaceuticals is a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate. Co.'s primary product candidate, REN001, is a potent and selective agonist of the peroxisome proliferator-activated receptor delta. Co. is developing REN001 in rare genetic diseases that typically present with myopathy and have high unmet medical needs, including primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. According to our Reneo Pharmaceuticals stock split history records, Reneo Pharmaceuticals has had 0 splits. | |
|
Reneo Pharmaceuticals (RPHM) has 0 splits in our Reneo Pharmaceuticals stock split history database.
Looking at the Reneo Pharmaceuticals stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Reneo Pharmaceuticals shares, starting with a $10,000 purchase of RPHM, presented on a split-history-adjusted basis factoring in the complete Reneo Pharmaceuticals stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
04/09/2021 |
|
| End date: |
04/25/2024 |
|
| Start price/share: |
$13.89 |
|
| End price/share: |
$1.65 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-88.12% |
|
| Average Annual Total Return: |
-50.31% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$1,187.57 |
|
| Years: |
3.05 |
|
|
|
|
|
